|

Orelabrutinib Clinical Trials

19 actively recruiting trials across 1 location

Also known as: ICP-022, Induction phase, Obinutuzumab, Rituximab, Yinuokai

Pipeline

Phase 2: 8Phase 3: 7Phase 4: 1Phase 2/3: 1

Top Sponsors

  • Ruijin Hospital5
  • Zenas BioPharma (USA), LLC2
  • The First Affiliated Hospital with Nanjing Medical University2
  • Beijing InnoCare Pharma Tech Co., Ltd.2
  • The First Affiliated Hospital of Soochow University1

Indications

  • Cancer17
  • Marginal Zone Lymphoma (MZL)5
  • Mantle Cell Lymphoma (MCL)4
  • Diffuse Large B-Cell Lymphoma3
  • Multiple Sclerosis2

Other17 trials

A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
Phase 3
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase 3
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
Phase 4
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
Phase 3
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Phase 3
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
Phase 2
Genotype-guided Treatment in DLBCL
Phase 3
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Phase 2/3
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
Phase 2
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial
Phase 2
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
Phase 2
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
Phase 2
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
Phase 2
Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
Phase 2
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL
Phase 2
Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
N/A
Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients
N/A

Maitland, Florida2 trials

A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

Neurology Associates, PA

Phase 3
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

Neurology Associates

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.